Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Significant Increase in Short Interest

Aeterna Zentaris Inc. (NASDAQ:AEZSGet Free Report) (TSE:AEZ) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 29,200 shares, an increase of 46.0% from the February 29th total of 20,000 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily volume of 16,800 shares, the short-interest ratio is currently 1.7 days.

Aeterna Zentaris Stock Performance

NASDAQ:AEZS opened at $2.19 on Friday. Aeterna Zentaris has a 1 year low of $1.36 and a 1 year high of $3.38. The business has a fifty day moving average of $1.90 and a 200-day moving average of $1.95. The stock has a market cap of $10.64 million, a price-to-earnings ratio of -0.46 and a beta of 1.56.

Analyst Upgrades and Downgrades

Separately, assumed coverage on Aeterna Zentaris in a report on Friday. They set a “sell” rating on the stock.

Get Our Latest Report on AEZS

Aeterna Zentaris Company Profile

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

See Also

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.